SYRS: חוב להון עצמי syros.com

To ensure therapeutic precision in oncology centers, Syros Pharmaceuticals (SYRS) is implementing strict oversight of biomaterial transportation. Production capacities and partner facilities are operating seamlessly, maintaining the pace of clinical trials. The business relies on the development of gene regulation methods to combat leukemia, targeting the precision medicine market. The market trend for the total debt-to-equity ratio is 0.00.

This metric measures the extent to which the financing structure relies on borrowed funds relative to equity, determining bankruptcy risk and the cost of servicing obligations. By analyzing the debt-to-equity ratio, an investor can assess the ability of Syros Pharmaceuticals (SYRS) to sustain costly clinical developments under strict FDA regulations without a critical debt burden.